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Assessment of circadian rhythms in humans:
comparison of real-time fibroblast reporter imaging
with plasma melatonin
Sibah Hasan,*,1 Nayantara Santhi,*,1 Alpar S. Lazar,*,1 Ana Slak,* June Lo,*
Malcolm von Schantz,*,† Simon N. Archer,*,† Jonathan D. Johnston,*,†
and Derk-Jan Dijk*,†,2
*Surrey Sleep Research Centre, and †Department of Biochemistry and Physiology, Faculty of Health
and Medical Sciences, University of Surrey, Guildford, UK
ABSTRACT We compared the period of the rhythm
of plasma melatonin, driven by the hypothalamic circa-
dian pacemaker, to in vitro periodicity in cultured
peripheral fibroblasts to assess the effects on these
rhythms of a polymorphism of PER3 (rs57875989),
which is associated with sleep timing. In vitro circadian
period was determined using luminometry of cultured
fibroblasts, in which the expression of firefly luciferase
was driven by the promoter of the circadian gene Arntl
(Bmal1). The period of the melatonin rhythm was
assessed in a 9-d forced desynchrony protocol, mini-
mizing confounding effects of sleep-wake and light-
dark cycles on circadian rhythmicity. In vitro periods (32
participants, 24.610.33 h, meanSD) were longer
than in vivo periods (31 participants, 24.160.17 h;
P<0.0001) but did not differ between PER3 genotypes
(P>0.4). Analyses of replicate in vitro assessments
demonstrated that circadian period was reproducible
within individuals (intraclass correlation0.62), but in
vivo and in vitro period assessments did not correlate
(P>0.9). In accordance with circadian entrainment
theory, in vivo period correlated with the timing of
melatonin (P<0.05) at baseline and with diurnal pref-
erence (P<0.05). Individual circadian rhythms can be
reliably assessed in fibroblasts but may not correlate
with physiological rhythms driven by the central circa-
dian pacemaker.—Hasan, S., Santhi, N., Lazar, A.S.,
Slak, A., Lo, J., von Schantz, M., Archer, S. N.,
Johnston, J. D., Dijk, D.-J. Assessment of circadian
rhythms in humans: comparison of real-time fibro-
blast reporter imaging with plasma melatonin. FASEB
J. 26, 2414–2423 (2012). www.fasebj.org
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Circadian rhythms are endogenously generated
rhythms that continue to oscillate with a near-24-h
period in the absence of periodic cycles in the external
environment (1). They are a fundamental characteris-
tic of most living systems. In humans, their disruption is
associated with negative health outcomes, such as ob-
served in shift work and circadian rhythm sleep disor-
ders (2–4). Mammalian circadian rhythms depend on a
network of interacting genes and proteins, including
transcriptional activators such as CLOCK, NPAS2, and
ARNTL (BMAL1), which induce transcription of the
clock genes Period (Per1, Per2, and Per3) and Crypto-
chrome (Cry1 and Cry2), as well as other clock-controlled
output genes. PER and CRY proteins form multimeric
complexes that translocate to the nucleus, where they
inhibit the transcriptional activators and thus suppress
their own expression (5, 6). The transcriptional-trans-
lational oscillator, which may interact with a cytosolic
metabolic oscillator (7), is operative in many tissues,
and circadian rhythms can be observed in the central
nervous system and in nearly all peripheral cell types,
although some differences may exist between central
and peripheral oscillators (8–11).
The near-24-h period of the transcriptional-transla-
tional feedback oscillator appears to be determined
primarily by post-transcriptional events, such as phos-
phorylation, which affects stability of the PER proteins
in particular (12, 13). The mammalian circadian system
is organized in a hierarchical manner such that a
central circadian pacemaker located in the suprachias-
matic nucleus directly drives rhythms in pineal melato-
nin synthesis, for example, through a well-defined
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neural connection, and also orchestrates peripheral
oscillators through neural, endocrine, and physiologi-
cal signals (14–16). The appropriate timing (phase) of
circadian behavioral and physiological rhythms relative
to external cycles is accomplished through entrainment
of the central circadian clock to the light-dark cycle
(17). According to models of entrainment (18–20) and
confirmed by many empirical observations (21–23), the
intrinsic period of the central circadian clock is a key
determinant of the phase relationship between the
endogenous oscillator and the light-dark cycle and
thereby a biological determinant of individual differ-
ences in behavior and physiology. In individuals with a
long intrinsic period of the central circadian pace-
maker, the nadir of the core body temperature rhythm,
the onset of nocturnal melatonin, and the preferred
timing of sleep are all located at a later clock time than
in individuals with a shorter circadian period (22, 23).
It is, therefore, necessary to assess circadian period in
order to identify causes underlying sleep timing disor-
ders.
In familial advanced sleep-phase syndrome (FASPS),
a mutation affecting a casein kinase Iε (CK1ε) phos-
phorylation site of PER2 (24) as well as a mutation in
the CK1 gene (25) have been reported. PER3 is also
phosphorylated by CK1ε (26, 27) and interacts with
PER1 and PER2 in nuclear translocation (27–29),
which is blocked by inhibition of CK1ε (30). Because
changes to the phosphorylation status of PER2 led to a
dramatic 4-h advance in sleep-wake timing and an
associated 1-h advance in intrinsic period in FASPS (24,
31), we previously hypothesized that a variable number
tandem repeat (VNTR) polymorphism in PER3
(rs57875989) would also be associated with circadian
period phenotypes because the polymorphism codes
for an 18-aa length difference that contains multiple
putative CK1ε phosphorylation sites (32). Indeed, de-
layed sleep-phase syndrome (DSPS) and evening pref-
erence are associated with polymorphisms in PER3 and
in particular with the VNTR polymorphism (32–36).
However, the absence of PER3 has been shown to have
negligible effects on circadian period in mice (37, 38),
and the VNTR polymorphism is thought now to exert
its effects primarily through sleep regulatory mecha-
nisms and not through effects on circadian period
(39–42). Nevertheless, direct assessments of the effects
of this or other clock gene variants on the period of the
human central circadian pacemaker are not available.
In fact, very few assessments of intrinsic circadian
period are available for any circadian rhythm sleep
disorder.
Assessment of the intrinsic period of the human
central circadian pacemaker requires that the period of
a reliable physiological marker of the central pace-
maker can be monitored over a prolonged period of
time (several days at least) while minimizing the influ-
ence of confounding factors, such as the light-dark
cycle, feedback from the sleep-wake cycle, and other
behaviors (19). Protocols include the classic free-run
protocol in sighted individuals living in the laboratory
(43); assessment of period in short-term constant rou-
tine or nap protocols (44–46); assessment of period of
temperature and melatonin rhythms in blind individu-
als living in society (47, 48); and forced desynchrony
protocols in which the sleep-wake cycle and associated
light-dark cycles are scheduled to a noncircadian pe-
riod, thereby distributing confounding factors uni-
formly across the circadian cycle (19, 49, 50). Theoret-
ically, the latter protocol should provide the most
robust assessment of central circadian period (19, 51).
These protocols are very costly and labor intensive, and
more recently, in vitro assessment of circadian period in
peripheral tissues has been introduced as a potential
alternative (46, 52, 53). Whether and how in vitro
assessments of intrinsic period relate to in vivo assess-
ments is an open question, because the latter reflect
directly circadian oscillations driven by the central
circadian clock of the brain, and in vitro protocols may
only reflect the properties of peripheral circadian
clocks in a particular cell type or tissue (6, 54, 55). The
availability of systems allowing the determination of in
vitro period on a large scale and at a low cost makes it
an important question whether individual differences
in the in vivo period of the central circadian pacemaker
are reflected in circadian rhythms assessed in the in
vitro systems. Some published data suggest that this is
the case (46), while others highlight the potential
confounding factors that could lead to differences
between circadian periods assessed by in vivo and in
vitro systems (56, 57). However, to date, no direct
comparison of in vitro assessments to in vivo intrinsic
period as assessed in a forced desynchrony protocol is
available. We therefore assessed in vitro circadian peri-
ods in cultured fibroblasts from participants character-
ized for the PER3 VNTR polymorphism and compared
those to the periods of the plasma melatonin rhythms
assessed in a forced desynchrony protocol in the same
individuals.
MATERIALS AND METHODS
Ethical permission and recruitment of human volunteers
The study was given a favorable ethical opinion by the
University of Surrey Ethics Committee and conformed to the
Declaration of Helsinki. A group of 271 young healthy male
and female participants without sleep complaints were re-
cruited through advertisements and posters. They all pro-
vided written informed consent and underwent a screening
procedure that included multiple health questionnaires as-
sessing physical and mental health, and psychological profile
including personality, intelligence, and emotional status, as
well as chronotype and sleep assessment (described in
ref. 36).
Participants were also genotyped for the PER3 VNTR as
described previously (36, 58), Thirty-six healthy individuals
(19 females and 17 males) aged 20.5–32.4 yr, who passed a
full physical examination and investigation including full
blood count and coagulation screen, biochemical profile,
and urine analyses for drugs of abuse, were selected to
participate in the study. The sample, which was stratified
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for the 3 genotypes of the PER3 VNTR, comprised 14
PER35/5 (homozygous for the longer, 5-repeat allele), 8
PER34/5 (heterozygous), and 14 PER34/4 (homozygous for
the shorter, 4-repeat allele) subjects. The protocol in-
cluded 2 wk of sleep diary and actigraphy monitoring
(Actiwatch L; Philips Respironics, Best, The Netherlands)
before the laboratory study period. The data from the first
week were used to compute the participants’ habitual
bedtime and wake time, which they were then required to
maintain until admission to the sleep laboratory and
compliance was monitored. Of the 36 individuals, 1 was
excluded (only for the in vivo part of the study) without
replacement after the adaptation night for medical rea-
sons. Thus, 35 continued in the in vivo study, and complete
melatonin data for reliable assessment of in vivo circadian
period were obtained in 31 subjects.
Assessment of circadian period in vivo
This version of the forced desynchrony protocol was modified
from Dijk et al. (59) and Czeisler et al. (49) and similar to the
implementation by Scheer et al. (60). It lasted 9 calendar days
(Fig. 1A). The protocol began with a baseline 8-h sleep
episode at habitual bedtime, followed by a 16-h wake period.
Following the second 16-h wake episode, subjects began the
forced desynchrony segment of seven 28-h days (sleep/wake:
9.33/18.67 h). During the forced desynchrony segment, each
successive sleep episode started 4 h later than the previous
one. Subjects spent their scheduled sleep episodes in individ-
ual bedrooms and their scheduled wake episodes in a light-
controlled communal area, which was shared with other
participants. To minimize relative coordination between the
28-h day and the endogenous circadian rhythm, the labora-
tory environment was maintained free of time cues, light
levels were kept low (5 lux) during the waking periods, and
participants slept in darkness (19).
To determine the in vivo circadian period, plasma samples,
with a scheduled sampling frequency of 1 to 2 h, were
collected during 28-h periods on 3 evenly spaced occasions, as
shown in Fig. 1A. During the first and third occasions, plasma
sampling was initiated several hours before the start of the
sleep episode, which in this segment of the protocol coin-
cided with the participants’ habitual bedtime. The second
sampling occasion coincided with the segment of the forced
desynchrony, where the sleep episode started 12 h out of
phase with the participants’ habitual bedtime. Plasma samples
were frozen at 20°C until use for melatonin quantification.
Melatonin levels were quantified using radioimmunoassay
(Stockgrand Ltd, Guildford, UK). The phase of the melato-
nin rhythm was defined as the time when melatonin concen-
tration levels reached 25% of the amplitude of the melatonin
rhythm [dim light melatonin onset (DLMO)]; a linear inter-
polation between the melatonin values just above and just
below the 25% value was used to identify this time (61). The
amplitude of the melatonin rhythm was defined as the
maximum melatonin concentration in a 24-h period minus
the baseline values (values observed during the day), with the
melatonin maximum value being the median of the 3 highest
values. The slope from a linear regression fitted to the 3
DLMOs was used to compute the in vivo circadian period for
each participant (24 hslope; ref. 48). Because of incom-
plete data collection during the second sampling occasion, in
one of the 31 participants only 2 DLMOs were available for
computing the circadian period.
Choice of in vitro system
Although melatonin is produced in human skin (62), it would
not be a convenient marker of the fibroblast circadian clock,
mainly because its synthesis is not rhythmic (63). We there-
fore used the Bmal1-luc assay in which expression of firefly
luciferase is driven by the promoter of the circadian gene
Figure 1. A) Double raster plot of the forced desynchrony protocol of participant BB0211. A cutaneous biopsy () was collected
during the baseline wake period (WP1) for isolating fibroblast cells used for the in vitro period assessment. After an 8-h baseline
sleep period (SP1), and a 16-h baseline wake period (WP2), the participant was scheduled to a 28-h sleep-wake cycle consisting
of sleep periods (black bars) of 9 h:20 min (SP2-8) and wake periods (tan bars) of 18 h:40 min (WP3-8). To better illustrate the
timing of the sleep periods, consecutive sleep periods are plotted both next to (hatched and black boxes) and below each other.
Melatonin profiles assessed from 3 blood sampling periods are plotted (dark red circles) together with the timing of the dim
light melatonin onset (red arrows). DLMOs occurred at 00:29 (SP2); 03:25 (WP5) and 01:30 (SP8), and the derived in vivo
period was 24.11. B) Detrended Bmal1-luciferase oscillation in fibroblasts from BB0211. The three full cycles included (from first
nadir) in the analysis are shown in the graph, after detrending by subtracting the 24-h moving average of the data included from
the raw data. The red curve indicates the largest sinusoidal component (Sin fit) in the detrended data, with its period and
goodness of fit (% of variance).
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Arntl (Bmal1). This approach is well established in the litera-
ture (52, 64) and therefore allows us to compare our data to
the literature.
Lentivirus production and titration
Lentivirus was constructed by cotransfection of the envelope
plasmid pMD2.G and the packaging plasmid psPAX2 (both
originally constructed in D. Trono’s laboratory, École Poly-
technique Fédérale de Lausanne, Lausanne, Switzerland)
into HEK293T cells (Thermo Fisher Scientific, Waltham, MA,
USA). The lentiviral particles contained a reporter construct
(pBluFpuro) in which expression of firefly luciferase is driven
by the mouse circadian Bmal1 promoter (Bmal1::luc), as
described previously (52, 64). All plasmids were generously
provided by Professor S. A. Brown (University of Zürich,
Zurich, Switzerland).
HEK293T cells were cultivated in 150-cm2 flasks with 30 ml
of HEK medium [Dulbecco’s modified Eagle medium
(DMEM) including Glutamax (Life Technologies, Carlsbad,
CA, USA), 10% fetal calf serum (FCS; Thermo Fisher Scien-
tific), 1% penicillin-streptomycin (Life Technologies), and 1
mM sodium pyruvate (Sigma-Aldrich, St Louis, MO, USA)] at
37°C and 5% CO2. These cells were transfected when 70–
90% confluent. For each 150-cm2 flask, 10.5 g of plasmid
(pMD2.G and psPAX2, 3 g for each; pBluFpuro, 4.5 g) at
a concentration of 100 ng/l was precomplexed with 30 l of
X-tremeGene 9 DNA Transfection Reagent (Roche, Basel,
Switzerland) in 865 l of Optimem (Life Technologies) at
ambient temperature for 30 min. Medium was then aspirated
from the HEK293T cells and replaced with 20 ml of fresh
HEK medium supplemented with the transfection reagent:
DNA complex. After 21 h at 37°C, transfection medium was
aspirated and replaced with HEK medium (20 ml/flask). At
48 h post-transfection, the lentivirus-containing HEK medium
was collected and replaced with fresh HEK medium. After a
further 24 h (72 h post-transfection), the lentivirus-contain-
ing HEK medium was again collected. On collection, each
batch was cleared of cell debris by centrifugation (3300 g, 10
min), and the resulting supernatant was sterilized by passing
through 0.22-m filters. Lentivirus particles were pelleted by
centrifugation (3500 g for 22 h at 4°C), resuspended in 50 l
of serum-free DMEM, and kept in aliquots at 80°C until use.
The stocks of lentivirus were titrated using QuickTiter Lenti-
virus Quantitation Kit (Cell Biolabs, San Diego, CA, USA) to
enable us to use the same amount of lentivirus particles for
the infection of each replicate of fibroblast cultures, thereby
minimizing any possible variation on the protocol and con-
sequently on the in vitro data.
Fibroblast isolation, infection, and synchronization
Fibroblasts were successfully isolated (as detailed below) from
32 participants including 4 subjects for whom in vivo period
was not available. In the middle of the afternoon on the day
before the scheduled baseline day of the forced desynchrony
protocol (red cross in Fig. 1A), one cutaneous biopsy (2 mm
diameter) per subject was collected from the upper buttock,
and fibroblast cultures were generated as described elsewhere
(46, 52). Briefly, the cells were cultivated in 35-mm dishes
with 0.2 ml of fibroblast medium [DMEM including 2 mM
glutamine (Thermo Fisher Scientific), 20% FCS and 1%
amphotericin B (Sigma Aldrich)] at 37°C and 5% CO2. From
3 to 7 replicates of fibroblasts per individual were cultivated
and used to assess circadian period. On reaching 40–50%
confluence, each 35-mm dish of fibroblasts was infected with
6  1010 lentivirus particles dissolved in 2 ml DMEM includ-
ing Glutamax, 20% FCS, 1% penicillin–streptomycin, and 8
g/ml protamine sulfate (Sigma-Aldrich). Afer 6 d, fibroblast
circadian rhythms were synchronized by treatment with 150
nM dexamethasone (Sigma-Aldrich) (65). After rinsing the
cells twice with phosphate-buffered saline, luciferin medium
[DMEM without phenol red, including 2 mM l-glutamine, 25
mM hydroxyethyl piperazineethanesulfonic acid (HEPES)
buffer (Life Technologies), 20% FCS, and 1% penicillin-
streptomycin] supplemented with 0.1mM of endotoxin-free
beetle luciferin (Promega, Madison, WI, USA) was added to
each dish. Bioluminescence was measured using a real-time
(10-min resolution) and light-tight luminometry device (Lu-
miCycle; Actimetrics, Wilmette, IL, USA) directly within the
culture incubator for 6–7 d at 37°C (8, 52). During the
process of expansion of fibroblast cultures (from fibroblast
isolation until bioluminescence measurement), the passage
number (1 passage difference between cell cultures) and
confluence state of our cells were tightly controlled in order
to minimize any potential effects on the in vitro data.
Assessment of circadian period in vitro
For each replicate of fibroblast measurements, the first circa-
dian cycle was excluded from the analysis, as it may vary
according to the condition of synchronization (52) and acute
effects of dexamethasone. Thereafter, 3 full cycles were
included between the first and fourth nadir from the mea-
surement, as shown in an example (Fig. 1B). The 24-h moving
average of the 3 cycles was subtracted from the raw data, in
order to remove any baseline drift. Next, circadian period was
computed with LumiCycle Analysis 2.44 software (46), which
identifies the sinusoidal component (Sin fit) with the largest
amplitude (from the amplitude spectrum) in the data. Then,
the damping of the oscillations was accounted for using a
negative exponential function. Our luminometry device al-
lowed simultaneous assessment of 32 cultures. In general, we
assessed period simultaneously in as many subjects as possi-
ble, and replicates within subjects were run on separate
occasions. All analyses were conducted in a procedure
blinded to genotype. An individual’s period was calculated as
the average of the replicates.
Statistical analysis
Data were analyzed using SAS v9.1 and v9.2 (SAS Institute,
Cary, NC, USA). Procedure Corr was used to assess Spear-
man’s rank-order correlations between variables. Correlations
were computed using the nonparametric model, which con-
verts each variable to ranks. Nonparametric correlations were
chosen because nonparametric methods are more robust, as
they rely on fewer assumptions (such as a monotonic relation-
ship, which is less restrictive than the linear relationship in
the parametric correlations). We used procedure Univariate
for the Kolmogorov-Smirnov 1-sample test (most conservative
for test of normality) to check that the frequency distributions
of in vivo and in vitro periods are normally distributed, and
also for the inspection of the probability plots of the resi-
duals for ascertaining the normal distributions. Procedure
NPAR1WAY [Kolmogorov-Smirnov 2-sample test (asymp-
totic)] was also used for the comparison of the in vivo with the
in vitro distributions. To compare in vivo and in vitro periods
and to assess the effect of genotype and subject on the
circadian period, procedure Mixed for analysis of variance
was applied. We used an unstructured covariance structure in
these analyses. Procedure Mixed was also used to compute
intraclass correlation coefficients (ICCs; reliability coeffi-
cients). ICCs were computed with their 95% confidence
intervals (CIs), as described previously (66). The ICC indi-
cates the ratio of the between-subject variance to the total
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variance (within-subject variance plus between-subject vari-
ance). The ICC can have any value between 0 and 1; values 	
0.5 (moderate to high ICC) are indicative of stability of
observations (replicates) within an individual. The ICC was
used to assess individuality and stability of a particular indi-
vidual’s repeated measurements of in vitro period.
RESULTS
In vitro circadian period in human fibroblast is longer
than in vivo period in healthy individuals
In total, data from 35 subjects were available (see Table 1). In
the forced desynchrony protocol, the timing of the
plasma melatonin rhythm drifted to a later hour in
most participants (see example in Fig. 1A), i.e., the in
vivo period was on average longer than 24 h. The
frequency distribution of the in vivo periods did not
deviate significantly (P	0.15) from a normal distribu-
tion. In vitro circadian rhythmicity could be reliably
detected in 32 subjects. The frequency distribution of
the in vitro periods also did not deviate significantly
(P	0.15) from a normal distribution, but the range of
periods was wider for the in vitro periods (23.7




cantly longer than in vivo periods (n31, 24.16
0.17 h;
P0.0001). The two distributions were statistically com-
pared and found to be significantly different
(KSa2.848; P	KSa0.0001).
Replicability of in vitro circadian period
measurements within individuals
Individuality and stability of the in vitro period
among the 116 measurements for the 32 subjects (3.6
replicates/individual on average) were assessed by
plotting all individual observations (Fig. 3). The data
show relatively low within-subject variation and also
considerable between-subject variation. Analysis of
variance to assess the effect of subject on the 116 in
vitro measurements yielded a significant effect of
subject (P0.0001; procedure Mixed). The ICC was
0.62 (95% CI: 0.45– 0.76). This confirms individuality
and stability of period in these 32 sets of human
fibroblasts.
Validity of in vivo circadian period as a measure of
endogenous circadian rhythmicity
A valid measure of intrinsic period of the central
circadian pacemaker should predict the timing of
physiology and behavior during entrainment. We
therefore assessed the association between both the
in vivo and in vitro periods and two markers of timing
of rhythmicity during entrainment. The timing of
melatonin relative to the start of the dark onset (i.e.,
habitual bedtime), also known as the phase angle of
entrainment, was evaluated. While no association was
found for the in vitro period (P	0.2), a significant
correlation was found between the in vivo period and
the timing of melatonin onset (rs0.420, P0.05;
Fig. 4B). This correlation was such that the shorter
the observed in vivo period, the more advanced the
timing of the melatonin rhythm relative to habitual
bedtime.
To establish whether the circadian periods were
also related to diurnal preference, which to a large
extent measures the preferred timing of sleep and




Total (n)PER34/4 PER34/5 PER35/5
Gender
Male (n) 7 3 7 17
Female (n) 7 5 6 18
Total (n) 14 8 13 35
Age (yr) 25.8 
 3.6 25.6 
 3.2 25.5 
 3.5 25.6 
 3.4
BMI (kg/m2) 22.2 
 1.9 22.6 
 2.6 21.9 
 2.8 22.2 
 2.4
MEQ 50.1 
 7.8 50.3 
 8.5 49.5 
 9.3 22.2 
 2.4
Demographics of the 35 subjects for whom we have in vivo and/or in vitro periods. In 28 subjects,
both in vivo and in vitro period assessments were available. In 4 subjects only in vitro periods and in three
3 subjects only in vivo period assessments were available. Values are means 
 sd. BMI, body mass index;
MEQ, morningness-eveningness questionnaire.
Figure 2. Frequency distributions of in vivo (A; n31) and in
vitro (B; n32) circadian periods (). Numbers of observa-
tions (individuals) were assessed for 8 period bins of 0.2 h
each (e.g., 23.723.9, 23.924.1).
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vitro assessments and the morningness-eveningness
questionnaire (MEQ) scores were computed. A sig-
nificant negative correlation between the in vivo
period and the MEQ score (rs0.369, P0.05; Fig.
4A) was observed. The direction of this correlation
shows that “morning types” have a shorter in vivo
circadian period than “evening types.” For the in vitro
periods, no significant correlations were observed,
either with the timing of melatonin onset relative to
habitual bedtime or the MEQ scores (P	0.2). Finally,
in vitro and in vivo periods were directly compared
(Fig. 5A). No significant correlation (P	0 .9) be-
tween in vivo and in vitro period assessments was
observed.
Effects of PER3 VNTR genotype
There was no statistically significant effect of PER3
genotype on either the in vitro circadian periods
(P	0.4), or in the in vivo periods (P	0.7; see distri-
bution of periods among genotypes in Fig. 5B). Even
when in vitro and in vivo periods were directly
compared separately for each genotype, no signifi-
cant correlation was found (see Table 2).
The ICCs computed per genotype showed that the
PER35/5 [ICC (95% CI)0.72 (0.46, 0.88), n11 subjects,
4.0 replicates/subject on average] and PER34/5 [ICC
0.64 (0.33, 0.87), n8, 3.8 replicates on average] had a
higher replicability of repeated measurements per indi-
Figure 4. Association of in vivo (top panels) and
in vitro periods (bottom panels) with morning-
ness-eveningness (in vivo: n31; in vitro: n32;
A) and the timing of melatonin onset relative to
bedtime (B). Horizontal gray lines in A indicate
cutoffs between diurnal types (16–30: definitely
evening type; 31–41: moderately evening type;
42–58: neither type; 59–69: moderately evening
type; 70–86: definitely morning type). B) Rela-
tionship between circadian periods (in vivo:
n31; in vitro: n30) and timing of melatonin
onset relative to habitual bedtime. Spearman
correlations computed over all individuals are
indicated at bottom right of each graph.
Figure 3. Individuality and stability of in vitro
period assessments in 32 participants. In each
participant, 3–7 replicates of fibroblasts were
cultivated and used to assess in vitro period.
Each assessment (dots) as well as the mean 
 se
(horizontal lines) is plotted for each partici-
pant. Data are ordered from short to long
periods. PER34/4: n  13 (black circles);
PER34/5: n  8 (dark red circles); PER35/5: n 
11 (red circles). Overall ICC (95% CI)  0.62
(0.45, 0.76), confirming individuality in these
32 human fibroblasts. Coefficient of within-
individual variance (95% CI)  0.01 (0.01,
0.01).
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vidual compared to the PER34/4 genotype [ICC0.42
(0.16, 0.73), n13, 3.2 replicates on average]. According
to established benchmarks, the first two ICCs indicate
high repeatability, whereas the third ICC indicates low
repeatability (67).
DISCUSSION
The results of this study confirm several previous ob-
servations on the characteristics of human circadian
rhythms and also provide new insights. The estimated
in vivo period of 24.16 
 0.17 h assessed with the forced
desynchrony protocol, the gold standard method to
determine the period of the central circadian pace-
maker, is remarkably similar to a previously reported
estimate of 24.15 
 0.2 h (50). The melatonin rhythm,
which is driven by the suprachiasmatic nucleus through
a well described neural pathway to the pineal, is one of
the most robust and widely used physiological markers
of endogenous circadian timing (61). The validity of
the in vivo assessment of melatonin as a measure of the
period of the central circadian pacemaker was also
confirmed by the significant correlation between pe-
riod and the timing of melatonin during entrainment
such that a shorter period was associated with an earlier
timing, which is in accordance with previous reports
(22, 23) and entrainment theory. In addition, this
period assessment correlated with diurnal preference
as reported by others (22) such that a shorter circadian
period was associated with morningness. All of this
suggests that this methodology to assess in vivo period is
reliable, reproducible and valid, albeit labor intensive
and expensive.
Assessments of circadian period in fibroblasts also
confirmed several previous observations. Our estimate
of the group average of fibroblast period of 24.61 

0.33 is similar to the values of 24.50 
 0.75 and 24.63 

0.47 h published by others (refs. 46, 52, respectively). In
the current study, in vitro periods were significantly
longer than in vivo periods by 27 min on average. In a
previous study (46) that used constant routine and nap
protocols, the in vitro periods were longer by 40 min
Figure 5. A) Association between in vivo and in
vitro circadian periods. Dashed line represents
the line of unity. B) In vivo (PER34/4: n12;
PER34/5: n6; PER35/5: n13) and in vitro
(PER34/4: n13; PER34/5: n8; Per35/5: n11)
periods by genotype. Each dot represents the
circadian period for each individual. Vertical
box plot represents the median (midline) with
the 25th (bottom rectangle) and 75th (top
rectangle) percentiles, and errors bars show the
10th and 90th percentile values per genotype.
Note that the 10th and 90th percentiles could
not be computed in PER34/5 (n9) because 9
individual data points are required.
TABLE 2. Summary statistics (Spearman’s correlations)
Variables compared and genotype
In vivo In vitro
n rs P n rs P
Circadian period vs. morningness-eveningness score
All 31 0.369 0.041 32 0.223 0.220
PER34/4 13 0.500 0.082 13 0.176 0.565
PER34/5 6 0.029 0.957 8 0.491 0.217
PER35/5 12 0.497 0.100 11 0.119 0.727
Circadian period vs. timing of melatonin onset
relative to habitual bed time
All 31 0.420 0.019 30 0.203 0.281
PER34/4 13 0.367 0.218 12 0.102 0.752
PER34/5 6 0.371 0.469 7 0.433 0.333
PER35/5 12 0.509 0.091 11 0.124 0.717
In vivo period vs. in vitro period
All 28 0.024 0.903
PER34/4 12 0.282 0.375
PER34/5 6 0.160 0.827
PER35/5 10 0.404 0.247
Nonparametric correlations between in vivo and in vitro period and morningness-eveningness score, as well as timing of melatonin onset
relative to habitual bedtime.
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than the in vivo periods in sighted individuals (mean
age: 39.80
19.27 yr) but not so in blind individuals
(mean age: 55.38
7.54 yr).
Differences between in vivo and in vitro periods and
their mutual association may depend on details of the
protocol or participants. In our study in healthy indi-
viduals without circadian rhythm sleep disorders, in
vivo periods did not correlate significantly with the in
vitro periods. This contrasts with a recent study in which
the in vitro periods were reported to be directly propor-
tional to the in vivo periods (46). These discrepancies
may be related to the fact that we used a forced
desynchrony protocol, whereas in a previous study (46),
constant routine (sighted subjects) or at-home mea-
surements (blind subjects) were used. The sample size
used to assess in vivo and in vitro period is substantially
larger in the current study than in the individual
studies in the previous study (46). However, the studies
also differ in a number of other important respects (see
Table 3). There is a considerable difference in age at
biopsy collection between subjects in the current study
(25.1
3.4 yr, n28) and the previous study (Basel
subjects: 51.11
22.79 yr, n9; Novosibirsk subjects:
30.55
8.97 yr, n11; Guildford blind subjects:
55.38
7.54 yr, n8). In the current study, biopsy
samples were obtained 1 d before the in vivo measure-
ments, whereas in the previous study (46), biopsies
were collected 2.44 
 1.67 yr (Basel), 6.27 
 2.00 yr
(Novosibirsk), and 11.38 
 1.85 yr (Guildford) after
the in vivo assessment. In addition, the proportion of
female subjects was 50.0% in our study, as compared to
33.3% (Basel), 81.8% (Novosibirsk) and 12.5% (Guild-
ford) in Pagani et al.
The lack of correlation between in vivo and in vitro
periods in our study and the moderate correlation
observed in Pagani et al. (46) raises the question as to
whether the in vitro period assessment is a reliable
characteristic of an individual, given that it is different
from the period of the central pacemaker. The high
ICC in our study demonstrates that also for our in vitro
periods, replicates from different subjects were both
stable and specific to the individual. This individuality is
observed even though it has become clear that in vitro
period assessment is exquisitely sensitive to factors such
as pH (56), and unidentified serum factors (57). This
implies that meaningful peripheral fibroblast period
assessment relies on in vivo signals. This is also in
addition to any further confounding effects on the
fibroblast clock that may be due to the overexpression
of an artificial Bmal1 promoter construct. Thus, while in
vitro period assessment may be reliable and reproduc-
ible within subjects, there are good reasons to explain
why this would not reflect the in vivo period originating
from the central circadian pacemaker.
Despite the fact that both in vitro and the in vivo
periods are constant characteristics of the individual,
the distributions of in vitro and in vivo period were very
different (P0.0001). This finding suggests that the
parameters of peripheral rhythms are quite distinctive
from central rhythms and can be interpreted as corrob-
orating the differences between the central and periph-
eral oscillators with respect to molecular mechanisms
(68) as well as the coupling of individual oscillators (9,
10, 69). These differences between central and periph-
eral oscillators are well emphasized in a recent study
that measured period and phase in multiple tissues in
wild-type and Per3/ mice (11). Thus, the different
period estimates may reflect some tissue-specific con-
trol of circadian clocks (6).
The PER3 VNTR genotype had no effect on circadian
period assessed either in vivo or in vitro. According to
the ICCs computed in each genotype for the in vitro
period data, the higher replicability in PER35/5 may
indicate that the circadian rhythms in this genotype are
more robust, and may be related to the fact that
PER35/5 homozygotes in one of our previous studies
(40) had stronger correlations between melatonin and
sleep-wake timing. Large-sample epidemiological stud-
ies have shown that the PER3 VNTR polymorphism
associates with individual differences in sleep timing
and thus represents a possible genetic regulator of
human circadian rhythms (32, 35, 36, 41). Subsequent
laboratory studies in smaller samples have suggested
that these effects are mediated by changes in sleep
homeostasis, and no effect of this polymorphism on the
circadian phase or amplitude of cortisol, melatonin and
RNA levels of several clock genes in leukocytes was
found in young adults (39, 40), although a small effect
of the PER3 VNTR on circadian phase in older individ-
uals was recently reported (70). The absence of an
effect of the polymorphism on either in vivo or in vitro
period is in accordance with those data in young adults,
although our current sample size will not have allowed
us to detect small differences in period.
In summary, our data show that the period of circa-
dian rhythms at the peripheral level can be reliably
assessed in fibroblasts and is stable within an individual.
Within this sample of healthy individuals without circa-
TABLE 3. Differences between the current study and a previous study (46)
Laboratory Female (%)
Sex (n)
Subjects (N) Average age at biopsy (yr) Average time to biopsy r r2 PF M
Basel 33.33 3 6 9 51.11 2.44 yr 0.679 0.460 0.0445
Novosibirsk 81.82 9 2 11 30.55 6.27 yr 0.824 0.680 0.0018
Guildford 12.50 1 7 8 55.38 11.38 yr 0.811 0.658 0.0268
SSRC 50.00 14 14 28 25.1 1 d 0.024 0.00058 0.9029
SSRC, Surrey Sleep Research Centre.
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dian rhythm sleep disorders, in vitro period does not
correlate with the in vivo period driven by the central
circadian pacemaker. However, in our present sample
in vivo period is a determinant of differences in the
timing of behavior. These data provide insights into the
differences between in vivo and in vitro circadian rhyth-
micity in humans and have implications for the use of in
vitro assessments in sleep and circadian medicine.
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